Tesamorelin Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians managing HIV-positive patients with lipodystrophy, tesamorelin — sold as Egrifta SV and the recently approved Egrifta WR — remains the only FDA-approved pharmacological option for reducing excess visceral abdominal fat. The supply disruption of Egrifta SV in 2024–2025, combined with the simultaneous launch of Egrifta WR, has created a complex access landscape. This guide provides a clinical summary of the current situation and actionable recommendations for your practice.

Clinical Background: Why Tesamorelin Matters for Your HIV Patients

HIV-associated lipodystrophy, and specifically excess visceral adipose tissue (EVAF), remains a clinically significant comorbidity for patients on long-term antiretroviral therapy. It is associated with increased cardiovascular risk, insulin resistance, metabolic syndrome, and significant psychosocial distress. Pathophysiology includes GH axis dysfunction — HIV-positive patients with lipodystrophy have demonstrably lower GH levels, creating a therapeutic rationale for GHRF analog therapy.

Tesamorelin's two Phase 3 randomized controlled trials demonstrated approximately 15–18% mean reduction in VAT at 26 weeks, with an 84% mean increase in IGF-1. Critically, effects are not sustained upon discontinuation — patients must continue indefinitely to maintain VAT reduction. This has important implications for access continuity: any prolonged interruption in therapy results in VAT returning toward baseline.

Timeline of the Egrifta Supply Disruption and Resolution

Egrifta SV experienced a supply disruption that required Theratechnologies to seek FDA approval of a Prior Approval Supplement (PAS) to their sBLA before resuming normal distribution. Key milestones:

March 25, 2025: FDA approves Egrifta WR (tesamorelin F8 formulation), a new once-weekly-reconstitution formulation designed to replace Egrifta SV

April 8, 2025: FDA approves Prior Approval Supplement for Egrifta SV sBLA — normal distribution of Egrifta SV resumes

September 5, 2025: Theratechnologies announces commercial availability of Egrifta WR — specialty pharmacies begin stocking and ordering

2026 (ongoing): Insurance plans progressively adding Egrifta WR coverage; Egrifta SV remains available during transition

Egrifta WR vs. Egrifta SV: Clinical Equivalence and Key Differences

The two products are not interchangeable and require separate prescriptions. Pharmacokinetic studies demonstrated bioequivalence between Egrifta WR and the original Egrifta (F1 formulation). Key differences:

Egrifta SV: 2 mg/vial; dose 1.4 mg (0.35 mL) SC daily; reconstituted with sterile water DAILY; requires refrigeration

Egrifta WR: 11.6 mg/vial (four vials per box, each sufficient for 7 daily doses); dose 1.28 mg (0.16 mL) SC daily; reconstituted with bacteriostatic water WEEKLY; stored at room temperature

The reduced injection volume and weekly reconstitution requirement of Egrifta WR represent a meaningful improvement in patient convenience, which may support adherence. Adverse reaction profiles are similar between formulations. Injection site reactions (25% vs 14% placebo) and arthralgia remain the most commonly reported adverse events.

Prior Authorization Landscape: What Insurers Require

Tesamorelin is a specialty-tier (Tier 4 or 5) medication requiring prior authorization with strict criteria. Standard PA requirements include:

Confirmed HIV diagnosis (ICD-10: B20) with documented antiretroviral therapy

HIV-associated lipodystrophy diagnosis (ICD-10: E88.1) with documented EVAF — ideally with CT or MRI imaging confirming excess visceral adipose tissue

Baseline waist circumference measurements (payers often require >100 cm in men, >88 cm in women)

Documentation that the patient does not have active malignancy, pituitary dysfunction, or pregnancy

The THERA Patient Support program assists with PA submissions and appeals. Enroll your patients by calling 1-833-23-THERA (1-833-238-4372) or visiting hcp.egriftawr.com. Having a completed enrollment form with patient consent ready when you first see an appropriate candidate will significantly reduce delays.

Monitoring Requirements for Patients on Tesamorelin

FDA-approved prescribing guidance requires ongoing monitoring during tesamorelin therapy:

IGF-1 levels: Monitor regularly. Consider discontinuation if persistently elevated (>3 SDS above mean for age).

Glucose/HbA1c: Evaluate glucose status prior to initiation and during therapy. Tesamorelin may cause glucose intolerance or worsen pre-existing diabetes.

Malignancy surveillance: Increased background risk in HIV patients. Discontinue if evidence of recurrent malignancy.

Fluid retention: Monitor for peripheral edema, arthralgia, carpal tunnel syndrome. Often resolves or improves with continued treatment.

Helping Your Patients Find Tesamorelin When Supply Is Tight

When individual patients are struggling to locate their prescription, medfinder for providers can help. medfinder calls specialty pharmacies on behalf of your patients to identify which locations can fill their tesamorelin prescription, and texts them the results. See our full provider guide on how to help your patients find tesamorelin in stock for more strategies.